Aurinia Pharmaceuticals (AUPH)

• Market cap: $2.04B
• 1 day: 17.69%
• 5 days: 23.11%
• 1 month: 36.93%
• 3 months: 35.37%
• 6 months: 87.65%
• Year to date: 76.74%
• 1 year: 114.98%
• 5 years: 11.91%
• 10 years: 425.42%
• Sector: Healthcare
• Industry: Biotechnology

About: Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Employees: 300